Literature DB >> 26687759

Lin28A enhances chemosensitivity of colon cancer cells to 5-FU by promoting apoptosis in a let-7 independent manner.

Tianzhen Wang1, Peng Han2, Yan He1, Ci Zhao3, Guangyu Wang3, Weiwei Yang1, Ming Shan4, Yuanyuan Zhu3, Chao Yang1, Mingjiao Weng1, Di Wu5, Lin Gao6, Xiaoming Jin1, Yunwei Wei7, BinBin Cui8, Guomin Shen9, Xiaobo Li10.   

Abstract

RNA-binding protein Lin28A is frequently over-expressed in human malignant tumors and is associated with tumor advance and poor prognosis. However, the expression pattern and functions of Lin28A in colon cancer are unknown. In this study, we detected the expression of Lin28A in colon cancer patients and tested the effect of Lin28A on the chemotherapeutic sensitivity of colon cancer cells to 5-fluorouracil (5-FU). As expected, we showed that Lin28A is up-regulated in 73.3 % of colon cancer patients. However, to our surprise, we found that oncogenic protein Lin28A-enforced expression in colon cancer cells enhanced the chemosensitivity of cancer cells to 5-FU via promoting the cell apoptosis. Further mechanisms study revealed that the effect of Lin28A increasing chemosensitivity of cancer cells is in a let-7 independent manner, but which is associated with decreasing the expression of DNA damage repair protein H2AX. Conclusively, here we reported an unexpected function of Lin28A, which may shed lights on fully understanding the physiological and pathological roles of this oncogene.

Entities:  

Keywords:  Apoptosis; Chemosensitivity; Colon cancer; H2AX; Lin28A

Mesh:

Substances:

Year:  2015        PMID: 26687759     DOI: 10.1007/s13277-015-4559-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  33 in total

1.  MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit.

Authors:  X Li; J Zhang; L Gao; S McClellan; M A Finan; T W Butler; L B Owen; G A Piazza; Yaguang Xi
Journal:  Cell Death Differ       Date:  2011-10-07       Impact factor: 15.828

2.  TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation.

Authors:  Inha Heo; Chirlmin Joo; Young-Kook Kim; Minju Ha; Mi-Jeong Yoon; Jun Cho; Kyu-Hyeon Yeom; Jinju Han; V Narry Kim
Journal:  Cell       Date:  2009-08-21       Impact factor: 41.582

3.  Lin28/let-7/Bcl-xL pathway: the underlying mechanism of drug resistance in Hep3B cells.

Authors:  Nan Tian; Ziwu Han; Zhaohui Li; Mingjie Zhou; Chunlei Fan
Journal:  Oncol Rep       Date:  2014-06-25       Impact factor: 3.906

4.  The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA.

Authors:  E G Moss; R C Lee; V Ambros
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

5.  Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy.

Authors:  Neelam Taneja; Mandel Davis; John S Choy; Michael A Beckett; Rachana Singh; Stephen J Kron; Ralph R Weichselbaum
Journal:  J Biol Chem       Date:  2003-10-15       Impact factor: 5.157

6.  Genetic analysis of the role of the reprogramming gene LIN-28 in human embryonic stem cells.

Authors:  Henia Darr; Nissim Benvenisty
Journal:  Stem Cells       Date:  2009-02       Impact factor: 6.277

7.  Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells.

Authors:  Kezhen Lv; Liqun Liu; Linbo Wang; Jiren Yu; Xiaojiao Liu; Yongxia Cheng; Minjun Dong; Rongyue Teng; Linjiao Wu; Peifen Fu; Wuguo Deng; Wenxian Hu; Lisong Teng
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240

8.  LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms.

Authors:  C E King; L Wang; R Winograd; B B Madison; P S Mongroo; C N Johnstone; A K Rustgi
Journal:  Oncogene       Date:  2011-05-30       Impact factor: 9.867

9.  Lin28 promotes transformation and is associated with advanced human malignancies.

Authors:  Srinivas R Viswanathan; John T Powers; William Einhorn; Yujin Hoshida; Tony L Ng; Sara Toffanin; Maureen O'Sullivan; Jun Lu; Letha A Phillips; Victoria L Lockhart; Samar P Shah; Pradeep S Tanwar; Craig H Mermel; Rameen Beroukhim; Mohammad Azam; Jose Teixeira; Matthew Meyerson; Timothy P Hughes; Josep M Llovet; Jerald Radich; Charles G Mullighan; Todd R Golub; Poul H Sorensen; George Q Daley
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

10.  Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2/M arrest and γ-H2AX foci formation in colorectal cancer.

Authors:  Kaiwu Xu; Zhihui Chen; Yi Cui; Changjiang Qin; Yulong He; Xinming Song
Journal:  Onco Targets Ther       Date:  2015-10-20       Impact factor: 4.147

View more
  14 in total

1.  Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.

Authors:  Madhav Madurantakam Royam; Chellan Kumarasamy; Siddhartha Baxi; Ajay Gupta; Nachimuthu Ramesh; Gothandam Kodiveri Muthukaliannan; Rama Jayaraj
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

Review 2.  RNA Binding Proteins in Intestinal Epithelial Biology and Colorectal Cancer.

Authors:  Priya Chatterji; Anil K Rustgi
Journal:  Trends Mol Med       Date:  2018-04-05       Impact factor: 15.272

3.  Hepatitis B virus x protein induces epithelial-mesenchymal transition of hepatocellular carcinoma cells by regulating long non-coding RNA.

Authors:  Yinji Jin; Di Wu; Weiwei Yang; Mingjiao Weng; Yafei Li; Xuefei Wang; Xiao Zhang; Xiaoming Jin; Tianzhen Wang
Journal:  Virol J       Date:  2017-12-19       Impact factor: 4.099

4.  Comparison of the expression and function of Lin28A and Lin28B in colon cancer.

Authors:  Tianzhen Wang; Yan He; Yuanyuan Zhu; Mingwei Chen; Mingjiao Weng; Chao Yang; Yan Zhang; Ning Ning; Ran Zhao; Weiwei Yang; Yinji Jin; Jing Li; Riju James Rajkumar Ezakiel Redpath; Lei Zhang; Xiaoming Jin; Zhaohua Zhong; Fengmin Zhang; Yunwei Wei; Guomin Shen; Dong Wang; Ying Liu; Guangyu Wang; Xiaobo Li
Journal:  Oncotarget       Date:  2016-11-29

5.  miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer.

Authors:  Tianzhen Wang; Dapeng Hao; Shucai Yang; Jianhui Ma; Weiwei Yang; Yuanyuan Zhu; Mingjiao Weng; Xiang An; Xuefei Wang; Yafei Li; Di Wu; Jing Tang; Chao Yang; Yan He; Lei Zhang; Xiaoming Jin; Guangyu Wang; Zhiwei Li; Tongsen Zheng; Hongxue Meng; Yukuan Feng; Xiaobo Li
Journal:  Cell Death Dis       Date:  2019-06-24       Impact factor: 8.469

6.  MicroRNA Biogenesis Pathway Genes Are Deregulated in Colorectal Cancer.

Authors:  Petra Vychytilova-Faltejskova; Alena Svobodova Kovarikova; Tomas Grolich; Vladimir Prochazka; Katerina Slaba; Tana Machackova; Jana Halamkova; Marek Svoboda; Zdenek Kala; Igor Kiss; Ondrej Slaby
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923

7.  Comprehensive characterization of cancer-testis genes in testicular germ cell tumor.

Authors:  Yuting Chang; Xuewei Wang; Yide Xu; Liu Yang; Qufei Qian; Sihan Ju; Yao Chen; Shuaizhou Chen; Na Qin; Zijian Ma; Juncheng Dai; Hongxia Ma; Guangfu Jin; Erbao Zhang; Cheng Wang; Zhibin Hu
Journal:  Cancer Med       Date:  2019-05-09       Impact factor: 4.452

8.  Silencing Lin28 promotes apoptosis in colorectal cancer cells by upregulating let‑7c targeting of antiapoptotic BCL2L1.

Authors:  Haogang Zhang; Yaguang Zong; Gongcai Qiu; Ruichun Jia; Xunzheng Xu; Fujing Wang; Dequan Wu
Journal:  Mol Med Rep       Date:  2018-01-25       Impact factor: 2.952

9.  Oncogene Lin28B increases chemosensitivity of colon cancer cells in a let-7-independent manner.

Authors:  Lihong Ma; Qi Zhao; Wenhao Chen; Yanqiao Zhang
Journal:  Oncol Lett       Date:  2018-03-13       Impact factor: 2.967

10.  Differences in the early stage gene expression profiles of lung adenocarcinoma and lung squamous cell carcinoma.

Authors:  Nitin Venugopal; Justin Yeh; Sai Karthik Kodeboyina; Tae Jin Lee; Shruti Sharma; Nikhil Patel; Ashok Sharma
Journal:  Oncol Lett       Date:  2019-10-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.